secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2024-04-15T23:59:59+00:00
Accession:  0001437749-24-011953
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reviva FY2023 net loss $39.3M; restates 2022; positive Phase 3 schizophrenia data; RECOVER-2 trial planned
--------------------------------------------------------------------------------

- Net loss $39.3M ($1.65/sh) for FY2023 vs restated $28.3M ($1.45/sh) for FY2022.
- Cash $23.4M as of Dec 31, 2023; completed $30M registered direct offering in Nov 2023.
- Restated FY2022 results due to ~$3.9M under-accrual of clinical trial expenses.
- Phase 3 RECOVER-1 met primary endpoint: 10.1-point PANSS reduction at 50mg vs placebo (p<0.001).
- Registrational RECOVER-2 trial starts Q2 2024; NDA submission for brilaroxazine targeted Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774924011953/0001437749-24-011953-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774924011953/rvph20240325_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-011953

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer